Evidence map›Paper›PMID 39346128›Full record

ArticleNanotechnology, science and applications2024

Green Nanotechnology Through Papain Nanoparticles: Preclinical in vitro and in vivo Evaluation of Imaging Triple-Negative Breast Tumors.

Aryel H Ferreira, Fábio L N Marques, Caroline C Real, Velaphi C Thipe, Lucas F Freitas, Caroline S A Lima, Larissa Estessi de Souza, Mara S Junqueira, Daniele de Paula Faria, Gustavo H C Varca and 2 more

Abstract read
In one paragraph

Article in Nanotechnology, science and applications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aryel H Ferreira *Nuclear and Energy Research Institute, IPEN-CNEN/SP, Sao Paulo, 05508-000, Brazil.ORCID 0000-0003-0846-4785
Fábio L N MarquesLaboratory of Nuclear Medicine (LIM-43), Departamento de Radiologia e Oncologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, 05403-911, Brazil.ORCID 0000-0001-7383-926X
Caroline C RealAarhus University, Department of Nuclear Medicine & PET-Centre, Aarhus, Denmark.ORCID 0000-0001-6096-3341
Velaphi C Thipe *Department of Radiology, Institute of Green Nanotechnology, University of Missouri, Columbia, MO, 65212, USA.ORCID 0000-0003-4426-6567
Lucas F FreitasNuclear and Energy Research Institute, IPEN-CNEN/SP, Sao Paulo, 05508-000, Brazil.ORCID 0000-0001-7934-9421
Caroline S A LimaNuclear and Energy Research Institute, IPEN-CNEN/SP, Sao Paulo, 05508-000, Brazil.ORCID 0000-0002-2408-1218
Larissa Estessi de SouzaLaboratory of Nuclear Medicine (LIM-43), Departamento de Radiologia e Oncologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, 05403-911, Brazil.ORCID 0000-0002-0540-7649
Mara S JunqueiraCenter for Translational Research in Oncology, Cancer Institute of the State of Sao Paulo, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0002-2404-6543
Daniele de Paula FariaLaboratory of Nuclear Medicine (LIM-43), Departamento de Radiologia e Oncologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, 05403-911, Brazil.ORCID 0000-0002-1766-2786
Gustavo H C VarcaNuclear and Energy Research Institute, IPEN-CNEN/SP, Sao Paulo, 05508-000, Brazil.ORCID 0000-0002-6545-237X
Ademar B LugãoNuclear and Energy Research Institute, IPEN-CNEN/SP, Sao Paulo, 05508-000, Brazil.ORCID 0000-0002-1737-3191
Kattesh V Katti *Department of Radiology, Institute of Green Nanotechnology, University of Missouri, Columbia, MO, 65212, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent advancements in nanomedicine and nanotechnology have expanded the scope of multifunctional nanostructures, offering innovative solutions for targeted drug delivery and diagnostic agents in oncology and nuclear medicine. Nanoparticles, particularly those derived from natural sources, hold immense potential in overcoming biological barriers to enhance therapeutic efficacy and diagnostic accuracy. Papain, a natural plant protease derived from Purpose: This study presents a novel approach in nanomedicine and oncology, exploring the potential of green nanotechnology by developing and evaluating technetium-99m radiolabeled papain nanoparticles ( Methods: Papain nanoparticles (P-NPs) were synthesized using a radiation-driven method and underwent thorough characterization, including size, surface morphology, surface charge, and cytotoxicity assessment. Subsequently, P-NPs were radiolabeled with technetium-99m ( Results: The synthesized P-NPs exhibited a size mean diameter of 9.3 ± 1.9 nm and a spherical shape. The in vitro cytotoxic activity of native papain and P-NPs showed low cytotoxicity in HUVEC, MDA-MB231, and 4T1 cells. The achieved radiochemical yield was 94.2 ± 3.1% that were sufficiently stable (≥90%) for 6 h. The tumor uptake achieved in the 4T1 model was 2.49 ± 0.32% IA/g at 2 h and 1.51 ± 0.20% IA/g at 6 h. In the spontaneous breast cancer model, 1.19 ± 0.20% IA/g at 2 h and 0.86 ± 0.31% IA/g at 6 h. SPECT/CT imaging has shown substantial tumor uptake of the new nanoradiopharmaceutical and clear tumor visualization. Conclusion: The findings underscore the potential of green nanotechnology-driven papain nanoparticles as promising agents for molecular imaging of breast and other tumors through SPECT/CT imaging. The results represent a substantial step forward in the application of papain nanoparticles as carriers of diagnostic and therapeutic radionuclides to deliver diagnostic/therapeutic payloads site-specifically to tumor sites for the development of a new generation of nanoradiopharmaceuticals.

Indexed as

enzymatic nanoparticleimaging probenanoradiopharmaceuticalspapain nanoparticleprotein nanoparticle

Identifiers

PMID39346128
PMCPMC11439364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.